These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 4119908)

  • 1. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Oct; 56(5):649-52. PubMed ID: 4119908
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-Azacytidine: a new active agent for the treatment of acute leukemia.
    Karon M; Sieger L; Leimbrock S; Finklestein JZ; Nesbit ME; Swaney JJ
    Blood; 1973 Sep; 42(3):359-65. PubMed ID: 4125239
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Strawitz JG; Weiss AJ; Yarbro JW
    Cancer Chemother Rep; 1974; 58(2):217-22. PubMed ID: 4133839
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I study of twice weekly 5-azacytidine (NSC-102816).
    Vogler WR; Arkun S; Velez-Garcia E
    Cancer Chemother Rep; 1974; 58(6):895-9. PubMed ID: 4141280
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of acute leukemia with 5-azacytidine (NSC-102816).
    McCredie KB; Bodey GP; Burgess MA; Gutterman JU; Rodriguez V; Sullivan MP; Freireich EJ
    Cancer Chemother Rep; 1973; 57(3):319-23. PubMed ID: 4127393
    [No Abstract]   [Full Text] [Related]  

  • 6. Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer.
    Wampler GL; Mellette SJ; Kuperminc M; Regelson W
    Cancer Chemother Rep; 1972 Aug; 56(4):505-14. PubMed ID: 5081594
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Feb; 56(1):95-101. PubMed ID: 5030811
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II study of strepozotocin (NSC-85998) in the treatment of advanced gastrointestinal cancer.
    Moertel CG; Reitemeier RJ; Schutt AJ; Hahn RG
    Cancer Chemother Rep; 1971 Jun; 55(3):303-7. PubMed ID: 5115851
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytosine arabinoside (NSC 63878) toxicity and antitumor acitivity in human solid tumors.
    Davis HL; Rochlin DB; Weiss AJ; Wilson WL; Andrews NC; Madden R; Sedransk N
    Oncology; 1974; 29(3):190-200. PubMed ID: 4412696
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study.
    Bukowski RM; LoBuglio A; McCracken J; Pugh R
    Cancer Treat Rep; 1980; 64(12):1387-8. PubMed ID: 7471126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
    Wiltshaw E; Kroner T
    Cancer Treat Rep; 1976 Jan; 60(1):55-60. PubMed ID: 1000519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma.
    Moertel CG; Reitemeier RJ; Hahn RG; Schutt AJ
    Cancer Chemother Rep; 1970 Dec; 54(6):471-3. PubMed ID: 4946016
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of 5-azacytidine (NSC-102816).
    Shnider BI; Baig M; Colsky J
    J Clin Pharmacol; 1976 Apr; 16(4):205-12. PubMed ID: 57124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days.
    Lomen PL; Baker LH; Neil GL; Samson MK
    Cancer Chemother Rep; 1975; 59(6):1123-6. PubMed ID: 56988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
    Bellet RE; Catalano RB; Mastrangelo MJ; Berd D
    Med Pediatr Oncol; 1978; 4(1):11-5. PubMed ID: 75498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in advanced gastrointestinal cancer.
    Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
    Cancer Chemother Rep; 1972 Apr; 56(2):267-9. PubMed ID: 5043230
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).
    Bellet RE; Mastrangelo MJ; Engstrom PF; Custer RP
    Neoplasma; 1973; 20(3):303-9. PubMed ID: 4125219
    [No Abstract]   [Full Text] [Related]  

  • 19. Twice weekly 5-azacytidine infusion in dissmeinated metastatic cancer: a phase II study.
    Vélez-Garcia E; Vogler WR; Bartolucci AA; Arkun SN
    Cancer Treat Rep; 1977 Dec; 61(9):1675-7. PubMed ID: 74283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of a nitrosourea (CCNU, NSC-79037) in advanced nonhematologic cancer.
    Perloff M; Muggia FM; Ackerman C
    Cancer Chemother Rep; 1974; 58(3):421-4. PubMed ID: 4841718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.